Global Antibody Drug Conjugates (ADC) Market Analysis Report 2022: A $13.8 Billion Market by 2028

company logo

Global Market for Antibody Drug Conjugates

Global Market for Antibody Drug Conjugates

Global Market for Antibody Drug Conjugates

Dublin, September 8, 2022 (GLOBE NEWSWIRE) — The “Global Antibody Drug Conjugates Market Size, Share and Industry Trend Analysis Report by Application, by Technology, by Regional Outlook and Forecast, 2022 – 2028” Report has been added to ResearchAndMarkets.com offering.

The global antibody drug conjugates market size is expected to reach $13.8 billion by 2028, rising at a market growth of 14.2% CAGR over the forecast period.

Antibody-drug conjugates (ADCs) are biopharmaceutical drugs that are particularly effective in treating cancer. ADCs are designed to kill cancer cells and leave healthy cells alone. Antibody-drug conjugates (ADCs) are a new class of anticancer drugs that have been created in recent years.

ADCs have proven to be a good substitute for conventional cancer treatments such as chemotherapy or combination therapy due to their low off-target effects and significant cytotoxicity at tumor locations. Several advances in antibody and drug engineering have resulted in highly effective tumor-targeting drugs with a wide therapeutic window.

There are already two ADCs on the market, such as Brentuximab vedotin and Trastuzumab emtansine, and many others are in clinical development. Enzymes together with prodrugs have proven to be a viable option. Horseradish peroxidase (HRP), a glycoenzyme, has been shown to convert the hormone indole-3-acetic acid (IAA) into a highly effective cytotoxic poison.

The use of this mixture of IAA and HRP in techniques such as gene-directed enzyme prodrug therapy (GDEPT) and antibody-directed enzyme prodrug therapy (ADEPT) has been studied (ADEPT).

For example, the market is likely to increase due to increased investment in this industry by key players such as Pfizer Inc., Piramal Pharma Solution, F. Hoffman La-Roche and Seagen, for the development of new ADCs for the treatment of cancer.

In addition, for example, to meet the growing demand for commercial ADCs in the UK, CDMO Piramal Pharma Solutions (PPS) committed USD 74.4 million for the formation of two state-of-the-art Antibody Drug Conjugates (ADC) production facilities in its current sites in Grangemouth, Scotland in February 2022.

Most corporations are conducting clinical trials to bring new products to market and achieve label expansion for products that have been previously approved. Seagen, for example, began phase 1 clinical trials of two new antibody-drug conjugates, SGN-B7H4V and SGN-PDL1V, in patients with advanced solid cancers in January 2022.

Additionally, the company, together with Astellas, completed patient recruitment for the K EV-103 cohort trial, which is used to treat first-line metastatic urothelial cancer (mUC). Market expansion is likely to be fueled by successful completion of clinical trial research and future product approval.

COVID-19 impact analysis

With the general COVID-19 pandemic, the expansion of many industries saw a decline in demand, however several other areas remained untouched and showed promising indicators of future growth.

COVID-19 has impacted various businesses in different ways. As activities within hospitals and healthcare facilities were severely limited due to social distancing and lockdown measures enacted by governments around the world, the outbreak of the COVID-19 pandemic had a massive impact on the drug and antibody conjugate business.

Market Growth Factors

The increasing cases of cancer

The increasing incidence of cancer in the population is a serious medical condition that occurs due to several unknown reasons, and this has raised a substantial need for advanced medical equipment to treat and cure various types of cancerous diseases.

Support equipment is widely used in companion diagnostics, personalized pharmaceuticals, and other disease diagnostics, such as disease risk assessment, and drug research and development. The increasing use of biomarkers in disease detection is one of the main factors anticipated to enhance the growth of the antibody-drug conjugates market in the coming years. Lung and breast cancer are the most existing cancers registered in recent years.

Increasing expenditures in the area of ​​health in developing countries

Emerging country governments are increasing spending on the health sector. Governments around the world plan to improve their health systems with this investment to offer better and more modern solutions and minimize cases of chronic diseases.

An aging population, a growing middle class, a growing proportion of lifestyle-related illnesses, an increased focus on public-private partnerships, an accelerating adoption of digital technologies, including telemedicine, as well as a Increased investor interest and FDI inflows in the last two decades are all fueling the growth of healthcare infrastructure.

Marketing constraint factor:

Higher cost in cancer treatment

The exorbitant cost of cancer therapy is the most critical challenge facing the drug-antibody conjugate market. Cancer drug prices are rising at the same time their success rates are rising. Cancer drugs can be expensive on a monthly basis, which most people can’t handle.

Even the rich, let alone the poor or the middle classes, struggle to pay the price for such expensive therapies. The cost of medications can be several times what many people earn in a month. The rising price of cancer diagnosis and treatment in poor countries is another major impediment to market growth.

Patients are increasingly selecting various low-cost screening techniques, limiting the number of patients who are screened for the purpose at hand.

Approvals and Tests:

  • August 2021 – GlaxoSmithKline received approval from the US Food and Drug Administration (FDA) for a new indication for JEMPERLI (dostarlimab-gxly), a programmed cell death receptor 1 (PD-1) blocking antibody ). This approval was intended to provide treatment for adult patients with advanced or recurring solid tumors with mismatch repair (dMMR) deficiency, as determined by an FDA-approved test, that have progressed during or after prior treatment that have no satisfactory substitute treatment options.

  • Sep-2021: Astellas Pharma and Seagen received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for PADCEV (enfortumab vedotin). This approval targeted radically unresectable urothelial carcinoma that had progressed after anticancer chemotherapy.

  • April 2021 – ADC Therapeutics has received US Food and Drug Administration (FDA) approval for ADC Therapeutics’ ZYNLONTA as third-line therapy for patients with relapsed or relapsed diffuse large B-cell lymphoma (DLBCL). refractory (r/r). This approval was intended to include patients with DLBCL developing from high-grade B-cell lymphoma and low-grade lymphoma.

company profiles

  • Takeda Pharmaceutical Company Limited

  • F. Hoffmann-La Roche Ltda.

  • AstraZeneca PLC

  • GlaxoSmithKline PLC

  • pfizer, inc.

  • Astellas Pharma, Inc.

  • Gilead Sciences, Inc.

  • Seagen, Inc.

  • ADC Therapeutics SA

  • Daiichi Sankyo Company, Limited

Study scope

per application

By Technology

  • Cleavable Linker

  • non-cleavable linker

  • Others

By Geography

  • North America

  • U.S

  • Canada

  • Mexico

  • Rest of North America

  • Europe

  • Germany

  • United Kingdom

  • France

  • Russia

  • Spain

  • Italy

  • The rest of Europe

  • Pacific Asia

  • Porcelain

  • Japan

  • India

  • South Korea

  • Singapore

  • Malaysia

  • Rest of Asia Pacific

  • LAMEA

  • Brazil

  • Argentina

  • United Arab Emirates

  • Saudi Arabia

  • South Africa

  • Nigeria

  • Rest of LAMEA

For more information on this report, visit https://www.researchandmarkets.com/r/om2qya

Attached file

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Leave a Comment